Compounds that improve M1 mAChR coupling to Gαq and away from PLA2 may yield Alzheimer's disease modifying benefits, by decreasing APP secretion, amyloid-β production and Tau hyperphosphorylation. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.